This Fund Bought Moderna Before It Nearly Tripled. See Its 2 New Stock Picks
Source Entity
Yahoo Finance
Bamco, the advisory arm of Baron Capital Group, recently saw significant gains after investing in Moderna during Q2 2026. The fund has now expanded its portfolio by acquiring new stakes in Fortune Brands Innovations and Harrow.
Strategic Portfolio Shifts at Baron Capital
Recent financial disclosures reveal that Bamco, the advisory arm of Ron Baron’s Baron Capital Group, has made calculated moves that underscore its growth-oriented investment philosophy. During the second quarter of 2026, the firm established a substantial position in Moderna (NASDAQ:MRNA), acquiring approximately 2 million shares. This timing proved exceptionally fortuitous, as the biotech firm saw its stock value nearly triple in August following a highly favorable Phase 3 clinical report. This maneuver highlights the fund’s propensity for identifying high-potential assets ahead of critical catalysts.
Diversification into Specialized Sectors
Beyond its success with Moderna, Bamco has signaled a broader strategy by initiating new stakes in the home and security products sector and the specialized pharmaceutical industry. The firm invested roughly $63.6 million for 1.2 million shares of Fortune Brands Innovations (NYSE:FBIN). This acquisition suggests an interest in stable, consumer-facing infrastructure and security-related markets, which often act as a hedge against the inherent volatility found in the biotechnology sector.
The Case for Harrow (NASDAQ:HROW)
Perhaps the most intriguing addition to the portfolio is the stake in Harrow (NASDAQ:HROW). Bamco acquired approximately 809,000 shares, valued at roughly $34.4 million. This move comes at a time when Harrow has faced significant market pressure, with the stock down approximately 26% year-to-date. By buying into a depressed asset, Baron Capital is betting on the long-term potential of Harrow’s specialized product pipeline.
Clinical Catalysts and Market Potential
At the core of the investment in Harrow is its portfolio of ophthalmic products. The company’s offerings include VEVYE, which is utilized for the treatment of dry eye disease, and IHEEZO, a chloroprocaine gel. These specialized treatments represent a niche segment of the pharmaceutical market that provides essential care, potentially offering significant upside if the company can overcome its recent market performance struggles and gain wider adoption for its therapeutic solutions.
Future Trends and Investment Philosophy
Looking ahead, the inclusion of both established security firms and specialized healthcare providers indicates that Bamco is balancing high-growth biotech bets with industrial stability. Investors watching these moves should monitor how Harrow navigates its current downward trend and whether the integration of VEVYE and IHEEZO into the broader market will serve as the necessary catalyst for a recovery. Baron Capital’s history of long-term holding suggests they are prepared to weather short-term volatility in pursuit of fundamental value.